Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
Status:
Completed
Trial end date:
2020-04-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of
pegloticase on clinical outcome, as defined by an serum uric acid level <6 mg/dL, in patients
with chronic, refractory gout.